Tablet capsule filled with repaglinide tablet and metformin tablet

Abstract

The invention relates to an oral-taking hard capsule, and in particular relates to a tablet capsule filled with a metformin tablet and a repaglinide tablet. The tablet capsule comprises a capsule and tablets in the capsule, wherein the capsule contains an upper capsule body and a lower capsule body; at least one tablet taking metformin as an active component and at least one tablet taking repaglinide as an active component are filled in the capsule. According to the tablet capsule filled with the metformin tablet and the repaglinide tablet, various active components in the capsule are not in contact with each other, thus the tablet capsule with good stability and convenience for processing is obtained.

Description

technical field

[0001] The invention relates to an oral hard capsule, in particular to a tablet capsule filled with metformin tablets and repaglinide tablets. Background technique

[0002] Metformin Repaglinide Tablets, English name: Metformin Hydrochloride and Repaglinide Tablets (PrandiMet), is Novartis’ drug for treating diabetes, and other dosage forms include capsules, etc. Patent CN201010118421 discloses the sustained-release preparation of the above-mentioned compound, and CN201110129531 discloses the above-mentioned Compound controlled release preparation. In the prior art, the two active ingredients of bivalent biguanide and repaglinide exist in the same minimum preparation unit, and there is a possibility of contacting the two in vitro. If the active ingredients are in contact with each other, there are the following disadvantages: 1. Due to the influence of multi-component mixing uniformity, it is difficult to quantify each component accurately; 2. During product...

Examples

Embodiment 1

[0021] Embodiment 1: see attached Figure 1-3 As shown, a tablet capsule filled with one repaglinide tablet; two metformin tablets. The capsule specification is size 0. The capsule shell is composed of a lower capsule body 1 and an upper capsule body 2 set, which are equipped with the above three cylindrical tablets coated with different colors, namely the first metformin tablet (containing metformin 250mg), repaglinide tablet (containing Linide 2 mg, made of microcrystalline, starch, lactose, pregelatinized starch slurry, plus carboxymethyl starch sodium, hard magnesium and silicon dioxide) and second metformin tablets (containing metformin 250 mg).

[0022] The first repaglinide tablet has a yellow gastric-soluble film coating, the metformin tablet has a red film coating, and the second repaglinide tablet has a black gastric-soluble film coating or both adopt the same color.

Embodiment 2

[0023] Embodiment 2: see attached Figure 4 As shown, a tablet capsule filled with a repaglinide tablet and a metformin tablet. The capsule specification is size 0. The capsule shell is composed of a lower capsule body 1 and an upper capsule body 2 set, which are equipped with the above two cylindrical tablets coated with different colors, namely repaglinide tablets (containing repaglinide 1mg), metformin tablets (metformin 250mg ). Repaglinide tablets are yellow stomach-soluble film-coated. The capsules come in a transparent pp bottle packaging.

[0024] The following will be explained in conjunction with the test example:

technical field

[0001] The invention relates to an oral hard capsule, in particular to a tablet capsule filled with metformin tablets and repaglinide tablets. Background technique

[0002] Metformin Repaglinide Tablets, English name: Metformin Hydrochloride and Repaglinide Tablets (PrandiMet), is Novartis’ drug for treating diabetes, and other dosage forms include capsules, etc. Patent CN201010118421 discloses the sustained-release preparation of the above-mentioned compound, and CN201110129531 discloses the above-mentioned Compound controlled release preparation. In the prior art, the two active ingredients of bivalent biguanide and repaglinide exist in the same minimum preparation unit, and there is a possibility of contacting the two in vitro. If the active ingredients are in contact with each other, there are the following disadvantages: 1. Due to the influence of multi-component mixing uniformity, it is difficult to quantify each component accurately; 2. During product...

Examples

Embodiment 1

[0021] Embodiment 1: see attached Figure 1-3 As shown, a tablet capsule filled with one repaglinide tablet; two metformin tablets. The capsule specification is size 0. The capsule shell is composed of a lower capsule body 1 and an upper capsule body 2 set, which are equipped with the above three cylindrical tablets coated with different colors, namely the first metformin tablet (containing metformin 250mg), repaglinide tablet (containing Linide 2 mg, made of microcrystalline, starch, lactose, pregelatinized starch slurry, plus carboxymethyl starch sodium, hard magnesium and silicon dioxide) and second metformin tablets (containing metformin 250 mg).

[0022] The first repaglinide tablet has a yellow gastric-soluble film coating, the metformin tablet has a red film coating, and the second repaglinide tablet has a black gastric-soluble film coating or both adopt the same color.

Embodiment 2

[0023] Embodiment 2: see attached Figure 4 As shown, a tablet capsule filled with a repaglinide tablet and a metformin tablet. The capsule specification is size 0. The capsule shell is composed of a lower capsule body 1 and an upper capsule body 2 set, which are equipped with the above two cylindrical tablets coated with different colors, namely repaglinide tablets (containing repaglinide 1mg), metformin tablets (metformin 250mg ). Repaglinide tablets are yellow stomach-soluble film-coated. The capsules come in a transparent pp bottle packaging.

[0024] The following will be explained in conjunction with the test example:

Images